福利彩票开奖结果全部

 
You are here: Home » News » Industries » Text

US-Based CEL-SCI Has Obtained an Approval From The Health Protection Administration

放大字体  缩小字体 Release date:2016-11-30  Views:223
Core Tip: US-based CEL-SCI has obtained an approval from the Health Protection Administration, Ministry of Health, of the Croatian Republic to

福利彩票开奖结果全部 us-based cel-sci has obtained an approval from the health protection administration, ministry of health, of the croatian republic to begin patient enrollment in phase iii clinical trial of its investigational cancer immunotherapy treatment, multikine (leukocyte interleukin, injection).

cel-sci anticipates enrolling approximately 40 patients in the phase iii trial at four clinical centers in croatia.

福利彩票开奖结果全部 croatia is the ninth country into which cel-sci has expanded its global phase iii trial.

福利彩票开奖结果全部 the company anticipates conducting the phase iii trial in approximately 100 clinical centers globally.

cel-sci plans to ramp up the patient enrollment in its phase iii clinical trial by adding a large number of clinical centers in the eight countries, where the company has already received approval to initiate the trial, and by adding new countries and centers across the globe.

these new centers are in addition to the phase iii clinical centers run by cel-sci's partners, including teva, israel and orient europharma, taiwan.

cel-sci ceo geert kersten noted the company is truly seeing major progress in advancing its study since engaging the two new cros ergomed and aptiv solutions, following the dismissal of the prior cro that was managing the study, inventiv, for lack of performance.

福利彩票开奖结果全部 "ergomed, which is responsible for about 95% of the patient enrollment in the trial, has invested $10 million of its own funds in the phase iii trial and, since then, has invested another $6 million in two other multikine collaborations with cel-sci.

福利彩票开奖结果全部 "both cros understand the potential of our science and share our vision, commitment, and diligence to bring this groundbreaking immunotherapy to market," kersten added.

福利彩票开奖结果全部 in november, cel-sci has announced that an independent data monitoring committee has completed a second interim review of the safety data from its pivotal phase iii study of multikine investigational new drug immunotherapy.

福利彩票开奖结果全部 the committee concluded that the data from the randomized, controlled phase iii study raised no safety concerns, and recommended that the phase iii study continue unmodified.

福利彩票开奖结果全部 the multikine phase iii study is enrolling patients with advanced primary, not yet treated, head and neck cancer.

福利彩票开奖结果全部 the phase iii study has been designed to demonstrate a statistically significant, 10% improvement in overall survival of enrolled patients who are treated with multikine plus standard of care (soc), compared to subjects who are treated with soc only.

multikine is intended to create an anti-tumor immune response to reduce local / regional tumor recurrence and thereby increase the survival of these patients.

 
Keyword: CEL-SCI, Medicine
 
[ NewsSearch ]  [ Add to Favorites ]  [ Tell a friend ]  [ Print ]  [ Close the window ]

 
Total0bar [View All]  Related Comments

 
Recommended Graphic
RecommendNews
Click Ranking
 组选奖号777 今天3d丹东全图手机牛材网 七星彩定头尾永久直码 大乐透一注一倍中多少 超跑娱乐app超跑娱乐最新版本